<div id="readability-page-1"><p>Vaxart (OTCMKTS:VXRT - Get Free Report) is expected to announce its  Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $65.50 million for the quarter. Investors can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 8, 2026 at 4:30 PM ET.</p><ul><li>3 Stocks Under $5 With Strong Analyst Upside Potential</li></ul><p>Vaxart (OTCMKTS:VXRT - Get Free Report) last posted its quarterly earnings data on Thursday, March 12th. The biotechnology company reported $0.24 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.32. The firm had revenue of $104.24 million for the quarter, compared to analysts' expectations of $35.95 million. Vaxart had a net margin of 6.88% and a return on equity of 33.83%. </p><h2>Vaxart Trading Down 1.6%</h2><p>Shares of Vaxart stock traded down $0.01 on Monday, hitting $0.76. 320,586 shares of the company traded hands, compared to its average volume of 704,864. The firm's 50-day simple moving average is $0.70 and its 200 day simple moving average is $0.54. The company has a market cap of $183.29 million, a P/E ratio of 12.63 and a beta of 1.18. Vaxart has a 12-month low of $0.26 and a 12-month high of $0.84. </p><h2>Analyst Upgrades and Downgrades</h2><p>Separately, Wall Street Zen upgraded shares of Vaxart to a &#34;buy&#34; rating in a research report on Friday, January 23rd.</p><p><b>Check Out Our Latest Analysis on Vaxart</b></p><h2>Hedge Funds Weigh In On Vaxart</h2><p>A number of large investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. raised its position in  Vaxart by 16.9% in the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company's stock worth $107,000 after purchasing an additional 34,075 shares during the period.  Invesco Ltd. raised its position in  Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 70,568 shares during the period.  Creative Planning purchased a new position in  Vaxart in the 2nd quarter worth $33,000.  Goldman Sachs Group Inc. purchased a new position in  Vaxart in the 1st quarter worth $31,000.  Finally, Jones Financial Companies Lllp raised its position in  Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock worth $196,000 after purchasing an additional 478,111 shares during the period. Hedge funds and other institutional investors own  18.05% of the company's stock. </p><h2>About Vaxart</h2> (Get Free Report)<p>Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics. </p><p>The company’s pipeline includes multiple vaccine candidates in various stages of development.</p><h2>Read More</h2><ul><li>Five stocks we like better than Vaxart</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVZYUlQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVZYUlQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Vaxart Right Now?</h2><p>Before you consider Vaxart, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxart wasn't on the list.</p><p>While Vaxart currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VXRT

LABU

<p>Vaxart (OTCMKTS:VXRT) is set to announce its Q1 2026 earnings on May 11, with expectations of $0.02 earnings per share and $65.50 million in revenue. The company previously reported $0.24 earnings per share for Q4 2025, exceeding estimates. Vaxart shares recently traded down 1.6% to $0.76, with a market cap of $183.29 million. Analysts have upgraded Vaxart to a "buy" rating, and institutional investors hold 18.05% of the stock. Vaxart focuses on developing oral vaccines using a proprietary platform.</p>

Vaxart (VXRT) Expected to Announce Quarterly Earnings on Monday